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Abstract
Background: Previous in vitro and animal studies demonstrated that transcription factors p-STAT6 and PU.1 are
required to induce interleukin (IL)-9 secretion by T helper (Th) 9 cells. It is believed that n factor-kappaB (NF-κB)
plays a role in eosinophil survival. The importance of these transcription factors in the pathogenesis of allergic
asthma (AA) in humans is poorly understood. We evaluated p-STAT6 and PU.1 expression in peripheral blood Th9
cells and NF-κB expression in eosinophils during late-phase airway inflammation in AA patients.
Methods: Nineteen adults with AA and 14 adult healthy individuals (HI) were examined. Peripheral blood collected
24 h before (baseline) and 24 h after bronchial allergen challenge. CD4+ cells and eosinophils were isolated by
high-density gradient centrifugation and magnetic separation. The percentage of Th9 cells and apoptotic
eosinophils was estimated by flow cytometry. p-STAT6 and PU.1 expression was expressed as mean fluorescence
intensity (MFI) in Th9 cells. NF-κB levels were expressed as MFI in peripheral blood eosinophils. Serum IL-9 and IL-5
levels were determined by enzyme-linked immunosorbent assay.
Results: At baseline, MFI of p-STAT6 and PU.1 in peripheral blood Th9 cells and MFI of NF-κB in eosinophils and, serum
IL-5 and IL-9 levels were greater in AA patients (P < 0.05). Decreased eosinophil apoptosis was seen in the AA group
compared with HI (P < 0.05). MFI of p-STAT6, PU.1, and NF-κB and serum levels of IL-5 and IL-9 were increased in the
AA group 24 h after challenge compared with baseline (P < 0.05). In the AA group, a correlation between serum IL-9
and Th9 cells (r = 0.7, P = 0.001) and MFI of PU.1 (r = 0.6, P = 0.01) 24 h after bronchial allergen challenge was observed.
A correlation between Th9 cells and MFI of p-STAT6 (r = 0.45, P = 0.03) as well as MFI of PU.1 (r = 0.5, P = 0.02) 24 h after
challenge was only observed in AA patients. A correlation between the MFI of NF-κB and eosinophil apoptosis was
observed in AA patients 24 h before (r = −0.46, P = 0.02) and after (r = −0.5, P = 0.02) challenge.
Discussions: p-STAT6 and PU.1 may be associated with Th9 cells and IL-9 production, whereas NF-κB and IL-5 may be
associated with reduced eosinophil apoptosis in allergen-induced late-phase airway inflammation.
Trial registration: ClinicalTrials.gov NCT02214303
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Background
The mechanisms of allergic asthma (AA) pathogenesis
remain poorly understood despite modern investigational
methods [1]. AA is a heterogeneous disease because the
environmental stimuli, exposure to allergens, and involve-
ment of different cells types and cytokines that participate
in asthma pathogenesis are different between individuals.
CD4+ T helper cells (Th) [2, 3] and eosinophils [4, 5] are
involved in the pathogenesis of AA. The differentiation of
CD4+ Th cells to different subsets depends on the type of
cytokines present in the local environment and other
stimuli. Interleukin-4 (IL-4) induces CD4+ T-cell prolifer-
ation and differentiation into Th2 cells that play an
important role in asthma pathogenesis [6]. IL-12 induces
the development of Th1 cells, which are important in cell-
mediated immunity and phagocyte-dependent protective
responses [7]. Transforming growth factor-β (TGF-β1),
IL-6, IL-1β, and IL-23 are required for the differentiation
of Th17 cells [8], which are associated with an increased
number of airway neutrophils and a more severe asthma
course. More recently, a newly identified T helper cell
subset, Th9 cells, were identified and shown to develop
under the influence of TGF-β and IL-4 stimuli [9, 10].
Th9 cells are thought to be an unstable subset that pro-
duce mainly IL-9 and are involved in allergic inflamma-
tion, some autoimmune diseases [11], and antitumor
immune responses in vivo [12]. It was recently shown that
Th9 cells differentiated from atopic children secrete
greater amounts of IL-9 in bronchial lavage than those
from non-atopic children [13]. Moreover, IL-9 is an im-
portant growth factor for repetitively stimulated T-cell
lines and induces lung eosinophilia after allergen stimuli.
Transcription factors often regulate the expression of
different cytokines and are essential for the regulation of
gene expression. Usually one or several specific transcrip-
tion factors are key for subset-specific differentiation, and
other transcription factors are shared between several sub-
sets. Th9 cell development has been less studied than
other CD4+ T helper subsets, but studies have shown that
Th9 cells develop under stimulation of IL-4-activated
signal transducer and activator of transcription protein-6
(STAT6). IL-4 and STAT6 are required to repress the
expression of Foxp3, which induces a Treg phenotype and
can repress IL-9 production [9, 10, 14]. STAT6 induces
interferon regulatory factor 4 (IRF4) that is important for
Th9 development [15]. Basic leucine zipper transcrip-
tion factor is required for IL-9 production in both hu-
man and mouse Th9 cells and cooperates with IRF4 in
binding to and activating the Il9 locus [16]. IL-4 and
STAT-6 activate the GATA3 gene, which is a main
Th2 cell type regulator. E26 transformation-specific
(ETS) family transcription factor PU.1 is a transcrip-
tion factor that promotes switching between Th2
and Th9 phenotypes. PU.1 plays an important role
in the development of Th9 memory cells and Th9
immunity [17].
Eosinophils develop from CD34+ pluripotent pro-
genitor cells under certain stimuli and in many cases
participate in the pathogenesis of AA. Progenitor
CD34+ cells express high numbers of IL-5 receptors
(IL-5R) and IL-5 generated by Th2 cells during asthma
act on the bone marrow to enhance the production of
eosinophils [18, 19]. Degranulated eosinophils release
cytotoxic substances that damage airway epithelial
cells [20]. IL-3, IL-5, and granulocyte-macrophage
colony-stimulating factor prolong eosinophil survival
in vitro by delaying apoptosis [21], while more recent
studies have shown that IL-9 possesses eosinophil
viability-enhancing effects [22]. Nuclear factor-kappaB
(NF-κB) is believed to be an important transcription
factor that mediates eosinophil survival because the
inhibition of NF-κB in humans and animals induces
eosinophil apoptosis [23].
This study investigated the role of the transcription
factors PU.1, STAT-6, and NF-κB in allergen-induced
inflammation in adult AA patients to try and mimic
real-life conditions because the importance of these
transcription factors in AA pathogenesis in humans has
not been completely elucidated. The aim of this study
was to evaluate STAT6 and PU.1 expression in peripheral
blood Th9 cells and NF-κB expression in eosinophils
during late-phase airway inflammation in AA patients
after inhaled allergen bronchial challenge.
Methods
The research protocol described below was approved by
the Regional Biomedical Research Ethics Committee of
the Lithuanian University of Health Sciences (BE-2-23).
The study was registered in the U.S. National Institutes
of Health trial registry ClinicalTrials.gov with identifier
NCT02214303.
Study population
We examined 33 nonsmoking adults (16 men and 17
women; median age, 26 years; interquartile range (IQR),
8) of which 19 patients had mild or moderate persistent
AA and 14 were healthy individuals (HI). Asthma was
diagnosed according to the revised 2012 GINA criteria
[24]. All the study participants were recruited from the
Department of Pulmonology and Immunology, Hos-
pital of the Lithuanian University of Health Sciences,
Kaunas. In all cases, informed consent was obtained
using a written consent form and was signed by the
study individuals. All participants were screened for inclu-
sion and exclusion criteria. Inclusion criteria were patients
with AA who had a clinical history of disease for ≥1 year,
with current symptoms, and positive results of the skin
prick test (≥3 mm) with Dermatophagoides pteronyssinus
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(D. pteronyssinus), birch pollen allergens, or five grass mix-
ture allergens. All study subjects had refrained from using
inhaled, nasal, or oral steroids for at least 1 month, long-
acting β2 agonists for at least 48 h, and short-acting β2
agonists for at least 12 h before the lung function test. Use
of antihistamines and antileukotrienes were stopped 7 days
before the skin prick test and the lung function test. Base-
line forced expiratory volume in 1 s (FEV1) was greater
than 70 % of the predicted value in all patients. All healthy
controls had normal spirometric values without airway
hyperresponsiveness, no history of lung or other systemic
immune diseases, and were nonatopic. None of the study
participants had a history of smoking (Table 1).
Study design
Study individuals were seen at the screening visit where
their eligibility for the study was checked based on inclu-
sion and exclusion criteria. This visit included physical
examination, spirometry, measurement of airway respon-
siveness to methacholine, and skin prick testing. At 24 h
before bronchial allergen challenge, spirometry was per-
formed and peripheral blood was collected from all eli-
gible study subjects. An allergen (D. pteronyssinus, birch,
or five grass mixture) for the bronchial challenge test in
patients with AA was chosen according to the results of
skin prick testing and clinical data in patients’ medical
records. In the case of multiple positive results of the skin
prick test, an allergen that most probably caused broncho-
constriction previously was chosen for specific bronchial
challenge. All healthy volunteers were challenged with a
D. pteronyssinus allergen. Bronchial allergen challenge was
performed at 8:00 in the morning, and spirometry was
reassessed every 10 min within the first hour and then
every hour for the subsequent 6 h. Physical examination,
spirometry, and peripheral blood collection were per-
formed again 24 h after bronchial allergen challenge. A
flow chart of the study is presented in Fig. 1.
Measurement of airway responsiveness to methacholine
Methacholine was nebulized into a 10-L reservoir with a
pressure nebulizer (Pari Provocation I; Pari, Stanberg,
Germany). Aerolized methacholine was inhaled through
a one-way valve at 5-min intervals starting with 15-μg
methacholine dose and doubling it until a 20 % decrease
in FEV1 from the baseline or the total cumulative dose
of 3.87 mg was achieved. The bronchoconstricting effect
of each dose of methacholine was expressed as a per-
centage of decrease in FEV1 from the baseline value.
The provocative dose of methacholine causing a ≥ 20 %
fall in FEV1 (PD20) was calculated from the log dose–re-
sponse curve by linear interpolation of two adjacent data
points [25, 26].
Skin prick testing
Standardized D. pteronyssinus, D. farinae, cat and dog
dander, 5 mixed grass pollen, birch pollen, mugwort,
Alternaria, Aspergillus, and Cladosporium allergen ex-
tracts for skin prick testing were used (Stallergenes
S.A., France) for all study individuals. Histamine hydro-
chloride (10 mg/mL) was used as a positive control,
and physiological saline, as a negative control. After
15–20 min, the diameters of wheals were measured.
The result was expressed as the mean of the longest
diameter of the wheal and the longest diameter perpen-
dicular to it. Reactions larger than 3 mm and at least
half the size of that produced by histamine were con-
sidered as positive [27].
Bronchial allergen challenge
Bronchial allergen challenge was performed with D.
pteronyssinus, birch, or five grass mixture allergens
(Stallergenes SA, Antony Cedex, France) at different
concentrations (0.1, 1.0, 10.0, and 33.3 IR/mL) using a
KoKo DigiDoser nebulizer (Sunrise Medical, Somerset,
PA, USA) [28]. A freeze-dried lyophilized allergen was
diluted with nonphenol saline. The results of the test
were considered positive if there was a fall in FEV1 of
20 % or more from the baseline value. Spirometry was
reassessed every 10 min within the first hour and then
every hour for the subsequent 6 h (in case of a late
asthmatic reaction occurrence). Spirometry was also
performed 24 h after bronchial allergen challenge. For
patients with pollinosis, bronchial allergen challenge
was not performed during the birch pollen and grass
pollen season.
Table 1 Demographic and clinical characteristics of study
population
Characteristics Allergic asthma
patients n = 19
Healthy subjects
n = 14
Age, median (range), years 25 (18–36) 27 (20–35)
Sex (male/female), n 10/9 7/6
Wheal diameter induced by
allergen, median (range), mm
6.8 (5–11) –
Sensitization to D. pteronyssinus/
birch/5 grass mixture allergen, n
12/4/3 –
PD20, geometric mean (range), mg 0.13 (0.03–0.42) –






Maximum fall in FEV1 after bronchial
allergen challenge during the first
hour, median (range), %
27 (22–34)* 2 (3–8)
FEV1, forced expiratory volume in the first second
PD20, provocative dose of methacholine causing a 20 % fall in FEV1
*P < 0.05 versus healthy individuals
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CD4+ T cells isolation from peripheral blood and
intracellular pStat6 and PU.1 staining in Th9 cells
Peripheral blood lymphocytes were isolated from periph-
eral blood samples on Ficoll-Paque gradient and resus-
pended in RPMI 1640 (Sigma- Aldrich, USA) containing
L-glutamine autologous plasma. CD4 T cells were sepa-
rated from all mononuclear cells (PBMCs) using a magnetic
separation kit (Miltenyi, USA). PBMCs were resuspended
in cold MACS buffer (containing: PBS pH 7.2, 0.5 % bovine
serum albumin [BSA] and 2 mM EDTA by diluting MACS
BSA Stock Solution 1:20 in autoMACSR Rinsing Solution)
(40 μL per 107 total cells) and incubated with Biotin-
Antibody Cocktail (CD8, CD14, CD15, CD16, CD19,
CD36, CD56, CD123, TCRγ/δ, and CD235a (Glycophorin
A) (10 μL per 107 total cells) for 5 min. After incubation,
20 μL of Anti-Biotin MicroBeads (conjugated to monoclo-
nal anti-biotin antibodies [isotype: mouse IgG1]) per 107
total cells was added, mixed, and incubated for additional
10 min at 4 °C. A LS column (Miltenyi Biotec, USA) was
prepared during this time by placing it in the magnetic field
of MACS Separator and washing it with 2 mL of MACS
buffer. A preseparation filter (30 μm Miltenyi Biotec, USA)
was rinsed with MACS buffer and placed on the top of the
column. The cells were then applied to the preseparation
filter/LS column, and the magnetically labeled non-CD4 T
cells depleted by retaining them on a column in the mag-
netic field of a Separator, while the unlabeled CD4 T cells
passed through the column. The cell fraction was eluted
with 5 mL of MACS buffer.
Cell fractions were centrifuged (400 g, 10 min, 4 °C), and
the pellet resuspended in 1 mL of RPMI 1640. Two million
cells per mL were activated for 5 h at 37 °C with phorbol-
12-myristate-13-acetate (Sigma-Aldrich) and ionomycin
(Invitrogen, USA) in the presence of a protein transport
inhibitor (BD GolgiStopTM, BD Biosciences, USA) to avoid
cytokine secretion. After the activation, the cells were fixed
with BD CytofixTM fixation buffer (BD Biosciences).
Permeabilization of the fixed cells was performed by adding
BD Perm/WashTM buffer (BD Biosciences) and stained by
adding human IFN-GMA Alexa 488, TGF-β Alexa 488, IL-
17A Alexa 488, IL-4 Alexa 488, IL-9 PERCP-CY5.5, pStat6
PE, PU.1 primary antibody, and secondary IgG2a + b
PE. Flow cytometry was performed on a FACSCalibur
flow cytometer (BD Biosciences). Results are reported
as the mean fluorescence intensity (MFI) of intracellu-
lar p-STAT6 and PU.1 in Th9 cells (CD4+ IL-9+ IFNγ−
TGFβ1
− IL-4− IL-17− cells).
Eosinophil isolation from peripheral blood and
intracellular NF-ĸB staining
Peripheral blood samples (20 mL) were diluted by adding
the same volume of PBS. The suspension was carefully
layered over Ficoll-Paque (ρ = 1.077 g/mL) in conical
tubes and centrifuged at 1000 g for 30 min at 20 °C in a
swinging bucket rotor without brake. A layer with mono-
nuclear cells (PBMCs) was removed and used for Th cell
isolation. Granulocytes were separated by hypotonic lysis
of erythrocytes. Later, the granulocyte pellet was resus-
pended in cold MACS buffer (containing: PBS pH 7.2,
0.5 % BSA, and 2 mM EDTA by diluting MACS BSA
Stock Solution 1:20 in autoMACSR Rinsing Solution)
(40 μL per 107 total cells) and incubated with Biotin-
Antibody Cocktail (biotin-conjugated monoclonal anti-
bodies against CD2, CD14, CD16, CD19, CD56, CD123,
and CD235a (Glycophorin A) (10 μL per 107 total cells)
for 10 min. After incubation, 20 μL of Anti-Biotin
MicroBeads (conjugated to monoclonal anti-biotin anti-
bodies [isotype: mouse IgG1]) per 107 total cells was
added, mixed, and incubated for additional 15 min at 4 °C.
A LS column (Miltenyi Biotec, USA) was prepared during
this time by placing it in the magnetic field of MACS
Separator and washing it with 2 mL of MACS buffer. A
preseparation filter (30 μm Miltenyi Biotec, USA) was
rinsed with MACS buffer and placed on the top of the
Fig. 1 The flowchart of the study
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column. The cells were then applied to the preseparation
filter/LS column, and the magnetically labeled non-
eosinophils depleted by retaining them on a column in the
magnetic field of a Separator, while the nonlabeled eosino-
phils passed through the column. The cell fraction was
eluted with 5 mL of MACS buffer.
Cell fractions were centrifuged (400 g, 10 min, 4 °C), and
the pellet resuspended in 1 mL of RPMI 1640. Two million
cells per mL were activated for 5 h at 37 °C with phorbol-
12-myristate-13-acetate (Sigma-Aldrich) and ionomycin
(Invitrogen, USA) in the presence of a protein transport
inhibitor (BD GolgiStopTM, BD Biosciences, USA) to avoid
cytokine secretion. After the activation, the cells were fixed
with BD CytofixTM fixation buffer (BD Biosciences).
Permeabilization of the fixed cells was performed by adding
BD Perm/WashTM buffer (BD Biosciences) and stained by
adding 20 μL of Alexa Fluor® 647 Mouse anti-NF-κB p65
(pS529) from BD, cat.no 558422 which recognizes the
phosphorylated serine 529 (pS529) in the transactivation
domain of the human NF-κB p65 subunit. NF-κB in general
is an ubiquitously expressed transcription factor. Optimal
activation of NF-κB requires phosphorylation (e.g. serine
phosphorylation) in the transactivation domain of p65.
Flow cytometry was performed on a FACSCalibur
flow cytometer (BD Biosciences). Results are reported
as the MFI of intracellular NF-ĸB expression in periph-
eral blood eosinophils.
The peripheral blood cell analysis was performed on
an automated hematology analyzer (Sysmex XE-5000,
Japan) at the Department of Laboratory Medicine,
Hospital of Lithuanian University of Health Sciences
Kaunas Clinics.
Detection of cytokines in serum
Serum cytokine levels were measured by the enzyme-
linked immunosorbent assay (ELISA) according to the
manufacturer’s instructions: the minimal detectable doses
of IL-9 and IL-5 were 0.1 ng/mL (Abcam, USA) and 5 pg/
mL (Abcam, USA), respectively.
Apoptosis assay
Isolated eosinophils were resuspended in the annexin-
binding buffer (pH 7.4) containing 50 mM HEPES,
700 mM NaCl, and 12.5 mM CaCl2 (Invitrogen, USA)
and incubated with fluorescein isothiocyanate-labeled
(FITC)-annexin V (Invitrogen, USA) and propidium iod-
ide (PI) for 15 min at room temperature in the dark.
After the incubation, apoptosis was analyzed by flow
cytometry using the CellQuest software (BD Biosciences,
USA). Apoptotic cells were quantified as the percentage
of the total population that was positive for FITC, but
negative for PI. Necrotic cells were positive for PI.
Statistical analysis
Statistical analysis was performed by using the Statistical
Package for the Social Sciences, version 20.0 for Win-
dows (IBM SPSS Statistics 20.0, USA). The normality
assumption of data was verified with the Shapiro–Wilks
test. All the data were distributed not normally and were
presented as median and ranges or interquartile range.
Because of a skewed distribution of the variables, non-
parametric tests were used. We analyzed two dependent
groups: one group comprised the same allergic asthma
patients 24 h before and 24 h after bronchial allergen
challenge; the second dependent group consisted of the
same healthy control individuals 24 h before and 24 h
after bronchial allergen challenge. The changes in data
before and after bronchial challenge in dependent groups
were evaluated for statistical significance by the Wilcoxon
test for paired analyses. Differences between two inde-
pendent groups were evaluated using the Mann–Whitney
U test. The Spearman rank test was used to assess rela-
tionships between variables. Statistical significance was
assumed when P <0.05.
Results
Characteristics of study population
No significant age and sex differences were documented
when both groups were compared. Only AA patients
showed positive skin prick test results. In the AA group,
12 patients were sensitized to D. pteronyssinus, four
patients to birch pollen allergens, and three patients to
five grass mixture allergens. Five patients had positive
skin prick test results for several inhalant allergens: birch
pollen, five grass mixture allergens, mugwort, and Alter-
naria. Three patients had positive skin prick test results
for D. pteronyssinus and five grass mixture allergens.
Demographic and clinical data of the study population
are presented in Table 1. Baseline FEV1 (% of predicted)
did not differ when comparing both groups. A signifi-
cant reduction in FEV1 after bronchial allergen challenge
during the first hour was only observed in AA patients.
At the baseline, AA patients had a significantly higher
peripheral blood eosinophil count compared with the
HI group (P < 0.01). The absolute peripheral blood
eosinophil number significantly increased in the AA
group 24 h after bronchial challenge compared with the
baseline values (P < 0.05). There were no significant dif-
ferences in peripheral blood leukocyte, lymphocyte, and
neutrophil counts before and after bronchial challenge
when comparing the AA and HI groups (Additional file 1:
Table S1).
Peripheral blood Th9 cells and serum IL-9
At 24 h after bronchial allergen challenge, the percent-
age of Th9 cells (Additional file 2: Figure S1) was higher
in the AA group compared with the control group and
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baseline values (1.32 % [0.78–2.12 %] vs. 0.11 % [0.05–
0.22 %] and 0.64 % [0.22–1.21 %], respectively, P < 0.05)
(Fig. 2a). At the baseline, the percentage of Th9 cells
was greater in the AA group compared with the HI
group (P < 0.05). There was no significant difference in
the percentage of Th9 cells in the HI group before or
after bronchial allergen challenge.
At the baseline, the serum IL-9 level was signifi-
cantly higher in the AA than the HI group (66.5 ng/
mL [31.3–82.4] vs. 36.3 ng/mL [28.2–42.9], respect-
ively, P < 0.05). At 24 h after bronchial allergen chal-
lenge, the serum IL-9 level was significantly increased
in the AA group compared with the baseline value and
the HI group (87.4 ng/mL [51.41–114.2] vs. 66.5 ng/
mL [31.25–82.4] and 38.9 ng/mL [32.6–46.3], respect-
ively, P < 0.01) (Fig. 2b). In the AA group, the percent-
age of Th9 cells and serum IL-9 levels correlated with
those at 24 h before (r = 0.52, P = 0.02) and 24 h after
(r = 0.69, P = 0.001) bronchial allergen challenge.
STAT6 and PU.1 transcription factors in Th9 cells
At 24 h after bronchial allergen challenge, there was a
significantly higher mean MFI of p-STAT6 in Th9 cells in
the AA group compared with the baseline value and the
HI group (84.6 MFI [67.2–105.5] vs. 51.7 MFI [34.9–84.9]
and 30.2 MFI [21.1–38.12], respectively; P < 0.01). The
mean MFI of p-STAT6 was also higher in the AA group
compared with the HI group at the baseline (51.7 MFI
[34.9–84.9] vs. 27.4 MFI [20.3–34.2], P < 0.01) (Fig. 3a–c).
At 24 h after bronchial allergen inhalation, the MFI of
PU.1 in Th9 cells was higher compared with the baseline
data and the HI group (98.6 MFI [68.45–115.68] vs. 65.2
MFI [51.3–80.1] and 42.4 MFI [36.51–52.4], respectively;
P < 0.01). The mean MFI of PU.1 remained unchanged
after bronchial allergen challenge in the HI group (38.7
MFI [28.4–55.6] vs. 42.4 MFI [36.5–52.4], respectively;
P > 0.05) (Fig. 4a–c). The percentage of Th9 cells corre-
lated with p-STAT6 (r = 0.45, P = 0.03), and the serum
IL-9 level correlated with PU.1 (r = 0.6, P = 0.01) and
the percentage of Th9 cells (r = 0.7, P = 0.001) after
bronchial allergen challenge in the AA group only.
Moreover, there was a significant correlation between
PU.1 and Th9 cells in the AA group 24 h after allergen
challenge (r = 0.5, P = 0.02). There was no significant
correlation between the percentage of Th9 cells and
serum IL-9 level or p-STAT6 and PU.1 in the HI group.
Peripheral blood eosinophil apoptosis, serum IL-5, and
NF-κB expression
Serum IL-5 levels were significantly greater in the AA
group than the HI group 24 h before bronchial aller-
gen challenge (42.3 pg/mL [28.7–55.6] vs. 16.2 pg/mL
[14.2–18.5], P < 0.01) (Additional file 3: Figure S2). At
24 h after bronchial allergen challenge, serum IL-5
levels were significantly increased in the AA group
compared with the baseline value and the HI group
(78.9 pg/mL [54.9–90.2] vs. 42.3 pg/mL [28.7–55.6]
and 16.2 pg/mL [14.6–19.3], respectively; P < 0.01).
There was no significant difference in the serum IL-5
level before and after bronchial allergen challenge in
the HI group.
At the baseline, a significantly lower percentage of
peripheral blood apoptotic eosinophils was observed in
the AA group compared with the HI group (3.45 %
[2.1–5.4 %] vs. 7.9 % [5.0–10.2 %] P < 0.001). At 24 h
after bronchial allergen provocation, the percentage of
apoptotic eosinophils decreased in the AA group com-
pared with the baseline value and the HI group (2.2 %
[0.9–3.12 %] vs. 3.5 % [2.1–5.4 %] and 8.0 % [6.6–9.1 %],
respectively; P < 0.001). Eosinophil survival in the HI
group remained the same even 24 h after bronchial aller-
gen challenge (Fig. 5a). Correlation between the percent-
age of apoptotic peripheral blood eosinophils and serum
IL-5 levels was only observed in AA patients 24 h after
bronchial allergen challenge (R = −0.78, P = 0.03), but
there was no significant correlation in this group 24 h
before allergen bronchial challenge. In addition, we did
not observe a correlation between the percentage of
apoptotic peripheral blood eosinophils and serum IL-5
levels in the HI group at any time point.
Fig. 2 Percentage of peripheral blood Th9 cells (a) and serum IL-9 concentration (b) in patients with allergic asthma and healthy individuals 24 h
before and 24 h after bronchial allergen challenge. Data are shown as median with minimum-maximum values (a) and as median with IQR (b)
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Our data showed a greater MFI of NF-κB in eosinophils
in the AA group 24 h after bronchial allergen challenge
compared with the baseline value and the HI group (99.3
MFI [79.5–153.5] vs. 51.4 MFI [39.2–70.26] and 27.8 MFI
[17.2–34.15], respectively; P < 0.001) (Fig. 5b). There was
no change in NF-κB in the HI group. Furthermore,
we observed significant negative correlations between
the MFI of NF-κB and eosinophil apoptosis 24 h be-
fore (r = −0.52, P = 0.02) and after (r = −0.46, P = 0.02)
allergen provocation.
Discussion
Our study has shown that p-STAT6 and PU.1 may be
important for Th9 cells and IL-9 production, whereas
NF-κB and IL-5 were associated with reduced eosinophil
apoptosis in allergen-induced late-phase airway inflam-
mation in AA patients.
A decade ago it was assumed that IL-4 and TGF-β
could induce IL-9 production from CD4+ T cells [29],
and this theory was proved by two independent groups
[9, 10]. Only a few CD4+ T-cell subsets are stable; often,
CD4+ T-cell subsets acquire new characteristic features
typical of different phenotypes dependent upon the type
of stimulating cytokine, and one polarized phenotype
can switch to another polarized phenotype [30]. Th9
cells are a CD4+ cell subset with great plasticity and
flexibility. Th9 cells require both IL-4 and TGF-β stimu-
lation because IL-4 alone stimulates the development of
CD4+ T cells into Th2 cells, and TGF-β alone induces
Treg cells. Th9 cells have lower Foxp3 expression than
Treg cells, lack Th2 cytokine production, and produce
high levels of IL-9. The plasticity of CD4+ T cells might
be explained by the presence of specific transcription
factors [31]: Th2 and Th9 cell phenotypes share com-
mon factors such as STAT6, PU.1, GATA3, c-maf, and
IRF4. Environmental factors activate the expression of
only one or several transcription factors, which induce
another CD4+ T-cell phenotype. Although the number
of Th9 cells is low and Th9 cells are closely related to
Th2 cells, these cells can be considered a unique and
separate CD4+ T-cell subset. There is a lack of studies
and consensus regarding Th9 cells; therefore, further
A
B C
Fig. 3 Diagram (a) represents the mean fluorescence intensity of p-STAT6 in Th9 cells in peripheral blood CD4+ cells in allergic asthma and healthy
individuals 24 h before and 24 h after bronchial allergen challenge. Data are shown as median (minimum-maximum values). Dot plot (b) represents
Th9 expression and dot plot (c) represents p-STAT6 expression in Th9 cells in one allergic asthma patient after bronchial allergen challenge
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studies on this new cell subset, especially in humans,
are needed. Many studies have used mouse models,
which are useful for the investigation of responses to
inhaled allergens. Murine models allow the applica-
tion of a broad range of immunological tools as well
as gene deletion in vivo. Studies of Th9 cells showed
that both human and murine Th9 cells do not ex-
press cytokines characteristic of other CD4+ T-cell
subsets except for IL-9; however, some authors
believe Th9 cells also produce IL-10. However, in
contrast to murine Th9 cells, IL-10 is not expressed
by human Th9 cells [10, 32, 33]. Other studies have
suggested the importance of Th9 cells in airway
allergic inflammation [14, 34–36], although some is-
sues remain to be resolved. To study Th9 cells and
their transcription factors as well as the role of eo-
sinophils in AA, we decided to challenge study indi-
viduals with an inhaled specific allergen as this
provocation model imitates natural allergen exposure
in humans.
There is some evidence that PU.1, a TS-family tran-
scription factor, is required for the generation of Th9
cells. In the study by Chang et al., naive T cells from
wild-type and PU.1 knockout mice were differentiated
under conditions favorable for the development of Th9
cells [36]. It was found that IL-9 protein secretion, IL-9
mRNA expression, and IL-9 intracellular staining were
decreased in Th9 cultures that lacked PU.1 expression.
This abovementioned study showed that PU.1 bound to
sites in the Il9 promoter specifically in Th9 cells and
promoted the switch between Th2 and Th9 phenotypes.
PU.1 protein is encoded by the SPI1 gene in humans,
and in the same study, the inhibition of SPI1 expression
in human Th9 cell cultures resulted in a significantly
lower production of IL-9 [36]. To identify associations
between human Th9 cells and PU.1, we applied the
bronchial challenge test to AA patients using an inhaled
specific allergen as this provocation model imitates nat-
ural allergen exposure quite well. We investigated PU.1
expression using flow cytometry analysis of Th9 cells
A
B C
Fig. 4 Diagram (a) represents the mean fluorescence intensity of transcription factor PU.1 in Th9 cells among peripheral blood CD4+ cells in
allergic asthma and healthy individuals before and after bronchial allergen challenge. Data are shown as median (minimum-maximum values).
Dot plot (b) represents Th9 expression and dot plot (c) represents PU.1 expression in Th9 cells in one allergic asthma patient after bronchial
allergen challenge
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from human peripheral blood and found a higher ex-
pression of this transcription factor in AA patients com-
pared with the control group, and the expression was
more prominent 24 h after allergen exposure. Moreover,
the MFI of PU.1 only correlated well with the percentage
of Th9 cells and serum IL-9 levels in the AA group 24 h
after bronchial allergen challenge. These data support
the findings from other studies that PU.1 is important in
Th9 cell differentiation.
STAT6 belongs to the family of transcription factors that
activate gene transcription in response to a particular
cytokine. It is a cytoplasmic protein that is activated by
tyrosine phosphorylation by cytokine receptor-associated
JAK (Janus) kinases after cytokine exposure. IL-4 activates
STAT6 and the expression of a very specific gene program
that regulates viability, proliferation, and differentiation of
the responding cell. STAT6 only recognizes phosphorylated
tyrosines on the cytoplasmic tail of the IL-4 receptor α
chain and does not interact with phospho-tyrosines on the
IFN-γ receptor [37]. JAK kinases, Jak1 and Jak3, bind to the
α and γ IL-4R chains, respectively, and are responsible for
the subsequent phosphorylation of the IL-4 receptor itself
as well as STAT6. The phosphorylated STAT6 monomers
then dimerize, translocate to the nucleus, and bind DNA to
activate transcription [38]. STAT6 is required for the modi-
fication of TGF-β-induced Treg development because Th9
cells develop when TGF-β and IL-4 act together. Mice
expressing constitutively active STAT6 are predisposed to
allergic disease [39]. We found greater pSTAT6 expression
in IL-9-producing cells from AA patients compared with
the HI group. A correlation between serum IL-9 levels and
pSTAT6 as well as between the percentage of Th9 cells and
pSTAT6 indicated the importance of this transcription
factor in the development and function of Th9 cells.
IL-9 is a signature cytokine of Th9 cells. Th2 cells, mast
cells, natural killer cells, Th17 cells, and Treg cells under
some conditions produce less clinically important amounts
of IL-9. It was shown that IL-9 increased the expression of
IL-5R on eosinophils and inhibited eosinophil apoptosis,
enhancing eosinophil development and promoting eosino-
phil maturation in synergy with IL-5 [22, 39]. Expression of
IL-9 in transgenic mice under the control of a lung-specific
Fig. 5 Peripheral blood eosinophil apoptosis (a) and mean fluorescence intensity of NF-ĸB in peripheral blood eosinophils (b) in patients with
allergic asthma and healthy individuals before and after bronchial allergen challenge. Data are shown as median with minimum-maximum values
(a) and median with IQR (b)
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promoter resulted in severe airway inflammation with eo-
sinophils and lymphocytes as well as mast cell hyperplasia
[40]. We investigated serum IL-9 levels in patients with AA
and HI before and after allergen challenge and found higher
serum IL-9 levels in patients with AA, which increased fur-
ther after allergen provocation. The IL-9 level correlated
with the percentage of peripheral blood Th9 cells 24 h after
allergen challenge in AA patients. These findings indicate
the important role of IL-9 and Th9 cells in allergen-
induced late-phase airway inflammation.
TGF-β-, IL-4-, and T-cell receptor-induced transcrip-
tion factors (including NF-κB non-canonical pathway)
co-stimulate acute Il9 expression. The Il9 promoter
region has multiple NF-κB binding sites [31, 41]. More-
over, TGF-β activates NF-κβ, which reduces eosinophil
apoptosis and in this way prolongs eosinophil survival
[42, 43]. In a recent study by Kankaanranta et al., cul-
tures of peripheral blood eosinophils from healthy,
atopic, or asthmatic donors (patients were allowed to
continue usual treatment with inhaled steroids or anti-
histaminic drugs) were investigated, and the data dem-
onstrated a major role for NF-κB in the TNF-β-induced
inhibition of eosinophil apoptosis [44]. Inhibition of NF-
κB leads to decreased airway eosinophilia in mice [45].
As delayed eosinophil apoptosis in asthma is a major
cause of prolonged eosinophil inflammation [46, 47], we
investigated peripheral blood eosinophil apoptosis 24 h
before and after bronchial allergen challenge. We found
a significantly higher percentage of apoptotic eosinophils
and higher serum IL-5 levels in the AA group compared
with the HI group at the baseline. However, the percent-
age of apoptotic eosinophils correlated with NF-κB ex-
pression in the AA group 24 h after bronchial allergen
challenge but did not correlate with the IL-5 levels.
Serum IL-5 levels were also increased in AA patients
after challenge. The HI group did not show any signifi-
cant changes in serum IL-5 levels or peripheral blood
eosinophil apoptosis. Our data support evidence from
previous studies that NF-κB and IL-5 are important in
prolonging eosinophil survival.
Conclusions
In summary, our data show associations between p-STAT6,
PU.1, and Th9 cells in adult AA patients. In addition, asso-
ciations between eosinophil NF-κB, serum IL-5, and per-
ipheral blood eosinophil apoptosis in late-phase airway
inflammation in AA patients were observed.
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